Research Article

Circulating Dynamics of SARS-CoV-2 Variants between April 2021 and February 2022 in Turkey

Murat Sayan,1,2 Ayse Arikan,2,3,4 and Murat Isbilen5

1Kocaeli University, Research & Education Hospital, PCR Unit, Kocaeli 41380, Izmit, Turkey
2Near East University, DESAM Research Institute, Nicosia 99138, Northern Cyprus, Mersin 10, Turkey
3Near East University, Department of Medical Microbiology & Clinical Microbiology, Nicosia 99138, Northern Cyprus, Mersin 10, Turkey
4Kyrenia University, Department of Medical Microbiology & Clinical Microbiology, Kyrenia 99320, Northern Cyprus, Mersin 10, Turkey
5Acibadem Mehmet Ali Aydinlar University, Graduate School of Health Sciences, Department of Biostatistics & Bioinformatics, Istanbul 34752, Turkey

Correspondence should be addressed to Ayse Arikan; aysearikancy@yahoo.com

Received 3 August 2022; Revised 19 September 2022; Accepted 24 September 2022; Published 15 October 2022

Academic Editor: Mejdi Snoussi

The diagnosis of new variants and monitoring their potential effects on diagnosis, therapeutics, and vaccines by genomic sequencing is essential to manage global public crises. In the current study, spike-genome next-generation sequencing was generated from 492 SARS-CoV-2 isolates to evaluate the mutations in Turkey from April 2021 to February 2022. The variant analysis was performed using (Coronavirus Antiviral and Resistance Database (CoV-RDB) by Stanford University). We revealed that the lineages Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Eta (B.1.525), variant of interest (VOI), lota (B.1.526), Zeta (P.2), Omicron (B.1.1.529), and Omicron BA.1 (B.1.1.529.1) were in the circulation in Turkey during the given period. The most common lineages were B.1.1.7, B.1.617.2, B.1.1.529, and B.1.1.529.1 SARS-CoV-2 variant circulation in Turkey seems highly heterogenetic; however, quite similar to the global epidemiologic analysis. The existence of globally circulating variants in the same chronological order in Turkey can be a guide for precautions, treatment, and vaccine options to be taken in the future.

1. Introduction

The pandemic character of the coronavirus disease 2019 (COVID-19) illness continues, with 550 million people getting infected and 6 million deaths [1]. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), belonging to the Coronaviridae family, is a single-stranded, positive-sense RNA virus. Due to the flexibilization of activities in various countries, various variants of concerns (VOCs) and VOIs has been emerged, changing the panorama of the evolution of the virus so that a more intense mutation rate can indeed be observed [2, 3]. Studies have demonstrated the negative impact of these variants on transmission, vaccines, and therapeutics [2–4]. As these variants have also spread globally, they have generated significant public health worldwide [5]. Currently, Omicron (B.1.1.529) lineages continue to be the circulating dominant variants of concern (VOCs) as it has been reported to be more contagious, despite lower disease severity than other lineages [6–8]. While the proportion of BA.2 lineage declines, BA.5 and BA.4 lineages have been reported to have been detected in 62 and 58 countries, respectively [9].

The first COVID-19 cases in Turkey were reported on March 9th, 2020. Since then, more than 15 million and approximately 100,000 deaths have been reported in Turkey [1]. According to the confirmed cases reported, it is noteworthy that there are three different periods in which the number of cases increased and peaked in Turkey. After the first cases were reported during Spring 2020, the number peaked in the first week of December 2020 (219,546
confirmed cases with 1.494 deaths) (the first wave). The second peak was Spring 2021, with 414.312 confirmed cases and 2.493 deaths (the second wave). Between July 2021 and December 2021, the number of confirmed cases per day ranged around 140.000, with approximately 1.500 deaths per day. The third phase was observed when the number of cases started to increase again in July 2021; since then, it peaked in January 2022 (712.091 confirmed cases with 1.922 deaths) (the third wave). At the end of February 2022, the number of subjects decreased, and this decrease continues in Spring [10].

Dissemination and evolution of new strains should be monitored to understand better, these genetic changes’ effect on the virus’ transmission rate and its impact on vaccines and therapeutics. Whole-genome sequencing and recently becoming more popular virtual phenotyping methods are powerful tools for molecular epidemiological analysis [11]. The study aimed to clarify the genomic diversity of SARS-CoV-2 strains circulating in three main cities of Turkey during five different periods of the pandemic.

2. Materials and Methods

2.1. Sampling. From April 2021 to February 2022, 492 SARS-CoV-2 strains were analyzed in the study. One hundred and forty-three strains in April 2021, 187 strains in August 2021, 28 strains in September 2021, 32 strains in December 2021, and 102 strains isolated in February 2022 were involved in the study. The strains were isolated from metropolitan cities, Istanbul, Ankara, and Kocaeli from COVID-19 cases in Turkey. These strains were selected as they were identified as potential variations by the mutation-specific SARS-CoV-2 polymerase chain reaction (PCR) screen.

2.2. SARS-CoV-2 RNA Isolation and Diagnosis. Viral RNA was extracted from the nasal/oropharyngeal swab fluids using the magnetic particle technic on the GeneRotex96 (Tianlong Science, Xi’an, China). The diagnosis of new coronavirus was performed using double gene target RT-qPCR (BioSpeedy, Istanbul, Turkey). N501Y/variant detection PCR kit (BioSpeedy, Istanbul, Turkey), and N501Y, delHV69–70, and E484K multiple mutation detection PCR kit (RTA Laboratories, Istanbul, Turkey) were applied for mutation screening. Positive strains were prepared for sequencing.

2.3. Next-Generation Sequencing (NGS). All the PCR products were purified for the NGS processing with the NucleoFast 96 PCR kit (Macherey-Nagel, Dueren, Germany). The purified product was quantitated by spectrophotometry using Nanodrop N1000 (Thermo Fisher, Wilmington, USA). Nucleic acids with concentrations adjusted to 0.2 ng/μl were sequenced on the Nextera XT (Illumina, CA, USA) sequencing platform.

The spike glycoprotein region located between 21709 and 23193 bps in the SARS-CoV-2 genome was aligned with the SARS-CoV-2 Wuhan Hu-1 isolate (GenBank accession number; MN908947.3). The primer pairs R: 5′-acacctgtgctcttaaacca-3′ and F: 5′-gacaaagttttcagatcctaggtttaca-3′ were used for sequencing [12], and sequencing was performed between the 118F–1652R primer region (~1500 bp) on the Miseq sequencing platform (Illumina, CA, USA). Based on BWA software, all sequencing data were reassigned with Miseq Reporter (https://bio-bwa.sourceforge.net/). The protocol for NGS PCR sequencing was generated as follows: at 45°C for 10 min, at 95°C for 2 min, then for 40 cycles; 95°C for 10 s, 57°C for the 30 s, and 72°C for 30 s.

2.4. Data Quality and Variant Calling. The sequenced data were inserted into the reference genome via BWA software [13] and analyzed with base recalibrator and apply for BQSR programs according to the recommendations of the Genome Analysis Toolkit (Broad Institute, Massachusetts, USA). The Genome Analysis Toolkit is used as an open source under a “new or revised” license and a BSD 3 clause and has been reedited to baseline reading quality. The Haplotype Caller program (Broad Institute, Massachusetts, USA) performed variant calling with mapping quality and read depth. Variant quality (QUAL) below 50, 15, and 500 were excluded from the analysis using the Variant Filtration program (Broad Institute, Massachusetts, USA). Sequences of samples for this region were constructed by modifying the mutations detected on the reference genome.

The variant/lineage classification and mutations of the strains were identified using the web tool Stanford University Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu/sierra/sars2/by-patterns/). All analyzes were performed and recorded one month after the sample collection. However, analyzes were repeated every three months to identify possible altered variants and patterns due to the update to the Stanford database. All circulating variants are analyzed in the Stanford web tool, but the relevant variant may not be detected in circulation despite the analysis. Therefore, variants for which data could not be obtained this way were defined as “not determined.”

2.5. Ethical Approval. This study received ethical approval from the Scientific Research Ethics Committee of the Near East University with the decision of 1383 NEU/2021/93. As the study was retrospectively conducted, no informed consent form was required.

3. Results

Between April 2021 and February 2022, 492 SARS-CoV-2 strains have been sequenced. Among these strains, 414 (64%) were identified as SARS-CoV-2 variants, while 78 (16%) were reported as wild type (WT). Circulating variants of SARS-CoV-2 in Turkey were evaluated using a web tool that provides similar results to the phylogenetic analysis in the current study [11]. Based on this analysis, between April 2021 and February 2022, 7 different lineages and a sublineage were reported among 414 sequences.

In April 2021, 5 different lineages including Alpha (B.1.1.7) (n = 100, 89%), Beta (B.1.351) (n = 5, 4%), Delta
The B.1.617.2 was relatively dominant during the five different periods in April and August 2021. Although B.1.617.2 had been in circulation since April 2021, Delta dominated during September and December 2021. Since the first emergence of Omicron in December 2021, Omicron and its subtype BA.1 became dominant in Turkey in February 2022 due to its rapid spread and increased transmissibility.

### 4. Discussion

Undoubtedly, molecular epidemiological analysis is invaluable for monitoring the evolution of new viruses and understanding the impact of emerging viruses on diagnostic kits, therapeutic agents, and vaccines. In the current study, spike-genome sequencing was generated from 492 SARS-CoV-2 isolates to evaluate the mutations in Turkey from April 2021 to February 2022. We revealed that the lineages Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Eta (B.1.525), VOI lota (B.1.526), Zeta (P.2), Omicron (B.1.1.529), and Omicron (BA.1) were in the circulation in Turkey in the time interval. The most common lineages were B.1.617.2, B.1.1.529, and B.1.1.529.1. It seems that SARS-CoV-2 variant circulation in Turkey is highly heterogeneous within the given period we examined. For almost 1–1.5 years, four different variants were dominant in Turkey. Following the global spread of SARS-CoV-2 at the beginning of 2020, intercontinental travel was restricted to reduce viral spread. After that, summer travel resumed in many countries in the further phases of the pandemic [14], which might have stimulated different types of viruses to spread between continents. This also shows us that the PCR diagnosis of SARS-CoV-2 should have high compliance with viral variability.

Alpha (September 2020), Beta (May 2020), Gamma (November 2020), and Delta (October 2020) were previously circulating VOCs, while Omicron (November 2021) is the only VOC in circulation [5]. According to our retrospective genome analysis, Turkey’s variation distribution during the
| Lineages          | Spike mutation patterns | CoV-RDB, n (%) | n |  |
|------------------|-------------------------|----------------|---|---|
| **B.1.1.7/Alpha** |                         |                |  |  |
| B.1.1.7/Alpha 205 | ∆69–70, ∆144, N501Y    | 205 (42)       | 1 |  |
|                  | 161 (79)                |                |   |  |
|                  | 7 (3)                   |                |   |  |
|                  | 6 (4)                   |                |   |  |
|                  | 5 (3)                   |                |   |  |
|                  | 4 (2)                   |                |   |  |
|                  | 3 (1)                   |                |   |  |
|                  | 3 (1)                   |                |   |  |
|                  | 2 (1)                   |                |   |  |
|                  | 2 (1)                   |                |   |  |
|                  | 2 (1)                   |                |   |  |
|                  | 2 (1)                   |                |   |  |
|                  | 3 (1)                   |                |   |  |
|                  | 1 (0.5)                 |                |   |  |
|                  | 1 (0.5)                 |                |   |  |
|                  | 1 (0.5)                 |                |   |  |
|                  | 1 (0.5)                 |                |   |  |
| **B.1.351/Beta** |                         |                |  |  |
|                  | D80A, D215G, Δ241–243, K417N, E484K, and N501Y | 11 (2)          |   |  |
| **B.1.617/Delta**|                         |                |  |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950Y | 82 (16)          |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, and T478K | 27 (33)         |   |  |
|                  | G142D, Δ156–157, R158G, L452R, and T478K | 9 (11)          |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 7 (9)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 6 (7)           |   |  |
|                  | K41X, T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 3 (4)           |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 3 (4)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, N950N, A1020V, and A222V | 2 (3)           |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 2 (3)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 2 (3)           |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N | 1 (1)           |   |  |
|                  | L452R and N501Y          | 1 (1)          |   |  |
|                  | T478K                   | 1 (1)          |   |  |
|                  | C136F, Δ144, A222V, Δ242–243, L452R, T478K, and E484Q | 1 (1)           |   |  |
|                  | K77T, G142D, Δ156–157, R158G, L452R, and T478K | 1 (1)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and V1228L | 1 (1)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and F1075L | 1 (1)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and V1104L | 1 (1)           |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and E1202Q | 1 (1)           |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and L1237I | 1 (1)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, A352V, L452R, T478K, D614G, P681R, N950N, and Q1072S | 1 (1)           |   |  |
|                  | G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and V1228L | 1 (1)           |   |  |
|                  | T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and N950N, and V1228L | 1 (1)           |   |  |
|                  | V42X, T95I, G142D, Δ156–157, R158G, E224Q, L452R, T478K, D614G, P681R, A688V, I850L, M869V, and D950N | 1 (1)           |   |  |
|                  | V83I, T95I, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, and D950N | 1 (1)           |   |  |
|                  | Δ156–157, R158G, T478K, D614G, P681R, and S1161SAPT | 1 (1)           |   |  |
| **B.1.525/Eta**  |                         |                |  |  |
|                  | A67V, Δ69–70, Δ144, and E484K | 4 (1)           |   |  |
|                  | A67V, Δ69–70, Δ144, and N501Y | 1 (25)          |   |  |
|                  | Q52R, A67V, Δ69–79, Δ144, and E484K | 1 (25)          |   |  |
|                  | Q52R, A67V, Δ69–79, Δ144, S22II, and E484K | 1 (25)          |   |  |
| **P.2/Zeta**     |                         |                |  |  |
|                  | D138Y L178I, S477N, A522S, D614G, Q675R, and A845S | 4 (0.8)         |   |  |
|                  | T95I, Δ144, and E484K    | 2 (50)         |   |  |
| **B.1.526/VoI lota** |                         |                |  |  |
|                  | F157S and A520S          | 1 (0.2)        |   |  |
|                  |                           | 1 (100)        |   |  |
COVID-19 pandemic is similar to the world in chronological order [5]. While lineage B.1.1.7 were documented at the highest rates in April 2021, B.1.351 and P.1 lineages were also reported globally [15]. The data on geographic spread and prevalence of VOCs supports our results as several SARS-CoV-2 lineages were reported in April 2021, while the Alpha dominated during the second wave in Turkey. In a recent study conducted in Turkey between March 2021 and December 2021, B.1.1.7 was dominant in April 2021 [16]. B.1.1.7 was reported as the most common lineage in Pakistan, one of the most populated countries in that month [17]. Similarly, the most common variant during Spring 2021 was reported Alpha in the United States [18]. Alpha is characterized by increased transmissibility, detected as the dominant variant in many countries, and the dominance continued until the summer of 2021 in Turkey and globally [18, 19].

According to the epidemiological reports on COVID-19, the Beta variant was the second most common variant detected globally after the Alpha variant in August 2021 [20]. Our genome analysis was also similar to global genomic analysis. We reported a lower rate for B.1.350 (Beta) and other variations, including B.1.525 (Eta) and B.1.526 (VOI lota), from early Spring 2021 to late Summer 2021, and observably, their incidence dropped sharply. Since the beginning of autumn, a sharp increase in the rate of the Delta variant has been observed, and it has been determined as the only variant in Turkey. As the pandemic continued, the primary concern of genetic diversity was whether these changes would impact drug and vaccine efficacy. According to the studies, people infected with B.1.617.2 were more likely to be hospitalized or have more severe outcomes than B.1.351 [21]. Delta was characterized by increased transmissibility compared to Alpha (40%–80%) [18]. In September 2021, the global rate of hospital admissions for COVID-19 accelerated sharply due to the Delta wave [22]. The highest rate of hospitalized infection occurred in the United States (n = ~87,000), followed by the United Kingdom (n = ~7,000) and France (n = ~6,000) [21]. Delta became dominant globally until December 2021 [23] and its effect continued in Turkey until then. Our findings showed that Delta was dominant in September–December 2021 in the country. During Delta’s dominance, the death rate in Turkey had nearly doubled [10]. The effect of the Delta variant on the rate of deaths demonstrates the importance of continuous monitoring of emerging variants and their potency on antibodies, vaccines, and diagnosis escapes, as variants of SARS-CoV-2 can spread rapidly worldwide.

Specifically, this retrospective epidemiologic analysis revealed that Omicron has been circulating with Delta since December 2021 in Turkey. Since it was first documented in November 2021, B.1.1.529 and its sublineages, including BA.1, BA.2, BA.3, BA.4, and BA.5, were emphasized to be monitored and comparatively evaluated for the virus characteristics [5, 24] because Omicron raises concerns as it may reduce antibodies produced by COVID-19 and the effectiveness of vaccines [25]. Since January 2020, nearly 12 million SARS-CoV-2 genomes have been uploaded to the GISAID data platform [26]. Although the number of submissions of the sequences continues to decrease compared to the previous months, among the lines, Omicron is still the dominant variant circulating globally [27]. According to the data on the geographic spread and the distribution of VOCs, while the rate of the sublineages BA.2 and BA.212.1 trends to decline, an acceleration was reported in the BA.4 and BA.5 on 13–19 June 2022 [27]. It should be noted that the limitation of surveillance systems, mainly the sequencing capacity of different countries, may also affect these trends.

### Table 1: Continued.

| Lineages               | Spike mutation patterns | CoV-RDB, n (%) |
|------------------------|-------------------------|----------------|
| B.1.1.529/Omicron       |                         | 28 (6)         |
| BA.1/Omicron           |                         | 79 (16)        |
| Wild type, no mutation |                         | 78 (16)        |
| Total                  |                         | 492 (100)      |

CoV-RDB: Stanford coronavirus antiviral and resistance database.
We only reported the BA.1 sublineage of Omicron in February 2022. However, the rapid spread of sublineages BA.4 and BA.5 makes us think of reaching these variants in Turkey in the future. Although Omicron has been shown to cause milder infections compared to other variants of SARS-CoV-2, it should always be considered that some Omicron sublineages may cause more severe disease than different Omicron varieties [28, 29]. In France, a recent study provided information on the severity of BA.2 compared to BA.1 sublineages of Omicron [30]. Therefore, continuing with the proper surveillance and precaution measures, the rate of the cases could be controlled in Turkey like in other countries.

The existence of globally circulating variants in the same chronological order in Turkey can be a guide for precautions, treatment, and vaccine options to be taken. Heterogenic variant dynamics in SARS-CoV-2 have led to diagnostic and vaccine development processes that we have not experienced before. On the other hand, the diagnosis and escape of vaccine may be possible in SARS-CoV-2 variants. Our findings, therefore, show how necessary viral genomic surveillance is.

**Data Availability**

No data were used to support this study.

**Ethical Approval**

This study received ethical approval from the Scientific Research Ethics Committee of the Near East University with the decision of 1383 NEU/2021/93.
Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

[1] The World Health Organization, “Coronavirus diseases dashboard,” 2022, https://www.google.com/search?q=turkey+coronavirus&ie=UTF-8&sourceid=chrome&ie=UTF-8.

[2] A. C. Brant, W. Tian, V. Majerciak, W. Yang, and Z. M. Zheng, “SARS-CoV-2: from its discovery to genome structure, transcription, and replication,” Cell & Bioscience, vol. 11, no. 1, p. 136, 2021.

[3] G. McLean, J. Kamil, B. Lee et al., “The impact of evolving-SARS-CoV-2 mutations and variants on COVID-19 vaccines,” mBio, vol. 13, no. 2, pp. 21 pages, Article ID e0297921, 2022.

[4] A. Yaqinuddin, A. Shafqat, J. Kashir, and K. Alkattan, “Effect of SARS-CoV-2 mutations on the efficacy of antibody therapy and response to vaccines,” Vaccines, vol. 9, no. 8, p. 914, 2021.

[5] S. Islam, T. Islam, and M. R. Islam, “New coronavirus variants are creating more challenges to global healthcare system: a brief report on the current knowledge,” Clinical Pathology, vol. 15, Article ID 2632010X221075S5, 7 pages, 2022.

[6] T. Nyberg, N. M. Ferguson, H. H. Nash et al., “Comparative analysis of the risks of hospitalized and death associated with SARS-CoV-2 Omicron (B.1.1.529) AND DELTA (b.1.617) variants in England: a cohort study,” The Lancet, vol. 399, pp. 00462–00467, 2022.

[7] A. C. Ulloa, S. A. Buchan, N. Daneman, and K. A. Brown, “Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada,” JAMA, vol. 327, no. 13, pp. 1286–1288, 2022.

[8] L. Veneti, H. Boas, A. Brathen Kristoffersen et al., “Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022,” Euro Surveillance, vol. 27, no. 4, Article ID 2200077, 2022.

[9] World Health Organisation, Weekly Epidemiological Update on COVID-19. 22 June 2022, World Health Organisation, Geneva, Switzerland, 2022.

[10] “COVID-19 dashboard Turkey,” 2022, https://covid19.who.int/region/euro/country/tr.

[11] M. Sayan, A. Arikan, and M. Isbilen, “Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus antiviral and resistance Database,” Journal of Comparative Effectiveness Research, vol. 11, no. 3, pp. 157–167, 2022.

[12] G. Korukluoglu, M. Kolukirik, F. Bayrakdar et al., “40 minutes RT-QPCR assay for screening spike S501Y and HV69-70del mutations,” bioRxiv Preprint, 2021.

[13] “Burrows-Wheeler Aligner.” https://bio-bwa.sourceforge.net/.

[14] E. B. Hodcroft, M. Zuber, S. Nadeau et al., “Spread of a SARS-CoV-2 variant through Europe in the summer of 2020,” Nature, vol. 595, no. 7869, pp. 707–712, 2021.

[15] World Health Organisation, Weekly Epidemiological Update on Covid-19. 27 April 2021, World Health Organisation, Geneva, Switzerland, 2021.

[16] F. B. Akcesme, T. K. Korulu, B. Erkal et al., “tracking the circulating SARS-CoV-2 variants in Turkey: complete genome sequencing and molecular characterization of 1000 SARS-CoV-2 samples,” bioRxiv Preprint, 2022.

[17] M. B. Sarwar, M. Yasir, N. F. Alikhan et al., “SARS-CoV-2 variants of concern dominate in Lahore, Pakistan in April 2021,” Microbial Genomics, vol. 7, no. 11, Article ID 000693, 2021.

[18] A. Bolze, S. Luo, S. White et al., “SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads,” Cell Reports Medicine, vol. 3, no. 3, Article ID 100564, 2022.

[19] R. Earnest, R. Uddin, N. Matluk et al., “Comparative transmissibility of SARS-CoV-2 variants delta and Alpha in new england, USA,” Cell Reports Medicine, vol. 3, no. 4, Article ID 100583, 2022.

[20] World Health Organisation, Weekly Epidemiological Update on COVID-19. 31 August 2021, World Health Organisation, Geneva, Switzerland, 2021.

[21] A. A. Butt, S. R. Dargham, H. Chemaitelly et al., “Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs. Beta variant in Qatar,” JAMA Internal Medicine, vol. 182, no. 2, pp. 197–205, 2022.

[22] Our World, Data, Share of SARS-CoV-2 sequences that are the delta variant, 2022, https://ourworldindata.org/grapher/covid-cases-delta?country=FRA%7EZA%7EGBR%7EESP%7EBWA%7EAUS%7EUSA%7EBEL%7EDEU%7ECAN%7EITA.

[23] Our World in Data, “Weekly new hospital admissions for COVID-19,” 2022, https://ourworldindata.org/grapher/weekly-hospital-admissions-covid.

[24] P. Colson, J. Delerce, M. Beye et al., “First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France,” Journal of Medical Virology, vol. 94, no. 7, pp. 3421–3430, 2022.

[25] Md Sohan, M. J. Hossain, and M. R. Islam, “The SARS-CoV-2 Omicron (B.1.1.529) variant and effectiveness of existing vaccines: what we know so far,” Journal of Medical Virology, vol. 94, no. 5, pp. 1796–1798, 2022.

[26] GISAID, https://www.gisaid.org/, 2022.

[27] World Health Organisation, Weekly Updates on COVID-19, World Health Organisation, Geneva, Switzerland, 2022.

[28] N. Wolter, W. Jassat, S. Walaza et al., “Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study,” The Lancet, vol. 399, no. 10323, pp. 437–446, 2022.

[29] J. Nealon and B. J. Cowling, “Omicron severity: milder but not mild,” The Lancet, vol. 399, no. 10323, pp. 412–413, 2022.

[30] P. Gautret, Y. T. Hoang, M. T. Jimeno et al., “The severity of the first 207 infections with the SARS-CoV-2 omicron BA.2 variant, in Marseille, France, december 2021-February 2022,” Journal of Medical Virology, vol. 94, no. 8, pp. 3494–3497, 2022.